Camber Capital Management’s Sanofi SNY Stock Holding History

Camber Capital Management’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000,000	Closed	-$38M	–	48
2022 Q3	$38M	Buy	+1,000,000	New	+$44.6M	1.16%	29
2022 Q1	–	Sell	-1,500,000	Closed	-$75.2M	–	44
2021 Q4	$75.2M	Buy	1,500,000 +500,000	+50%	+$24.7M	2.58%	18
2021 Q3	$48.2M	Buy	+1,000,000	New	+$50.8M	1.48%	27

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Camber Capital Management's SNY Position: Q4 2023 in Review

Camber Capital Management sold out of Sanofi (SNY) in Q4 2023, closing a stake of 2,750,000 shares — an estimated $148M sold.

Camber Capital Management first reported a position in SNY in Q2 2021 and held it in 10 quarters. The position peaked at $339M in Q4 2022. 708 funds tracked by Wall St. Rank hold SNY as of Q4 2023.

Camber Capital Management reported no remaining Sanofi position as of Q4 2023 after selling out during the quarter.
Camber Capital Management sold 2,750,000 Sanofi shares in Q4 2023, an estimated $148M.
Camber Capital Management first reported a position in Sanofi in Q2 2021 and held it in 10 quarters.
Camber Capital Management's Sanofi position peaked at $339M in Q4 2022.
708 funds tracked by Wall St. Rank held Sanofi as of Q4 2023.

Based on Camber Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.